Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Stock Information for GlucoTrack Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GlucoTrack Inc.

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
Glucotrack, Inc. Encourages Shareholders to Vote
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.